Skip to main content

Genetic switches with big potential

Nobel scientist uncovered tiny genetic switches with big potential

Harvard geneticist Gary Ruvkun vividly remembers the late-night phone call with his longtime friend and now 2024 Nobel Prize in Medicine co-laureate Victor Ambros, when they made their groundbreaking discovery of genetic switches that exist across the tree of life.

It was the early 1990s. The pair, who had met a decade earlier and bonded over their fascination with an obscure species of roundworm, were exchanging datapoints at 11 pm—one of the rare moments Ambros could steal away from tending to his newborn baby.

"It just fit together like puzzle pieces," Ruvkun told AFP in an interview from his home in a Boston suburb, shortly after learning of the award on Monday. "It was a eureka moment."

What they had uncovered was microRNA: tiny genetic molecules that act as key regulators of development in animals and plants, and hold the promise of breakthroughs in treating a wide range of diseases in the years ahead.

Although these molecules are only 22 "letters" long—compared to the thousands of lines of code in regular protein-coding genes—their small size belies their critical role as molecular gatekeepers.

"They turn off target genes," Ruvkun explained.

"It's a little bit like how astronomy starts with looking at the visible spectrum, and then people thought 'If we look with X rays, we can see much higher energy events,'" he added.

"We were looking at genetics at much smaller scales than it had been looked at before."

Dismissed at first

Their discovery had its roots in early investigations into C. elegans, a one-millimeter-long roundworm.

Ambros and Ruvkun were intrigued by the interplay between two genes that seemed to disrupt the worm's normal development—causing them either to stay in a juvenile state or acquire adult features prematurely.

The genetic information contained in all our cells flows from DNA to messenger RNA (mRNA) through a process called transcription, and then on to the cellular machinery where it provides instructions on which proteins to create.

It's through this process, understood since the mid-20th century, that cells become specialized and carry out different functions.

But Ambros and Ruvkun, who began their work in the same lab before moving to different institutions, discovered a fundamentally new pathway for regulating gene activity through microRNAs, which control gene expression after transcription.

They published their findings in back-to-back papers in Cell in 1993, but at first, the discovery was dismissed as an esoteric detail, likely irrelevant to mammals.

"We were considered an oddity in the world of developmental biology," Ruvkun recalled. Even he had little idea their work would one day be celebrated by the wider scientific community.

That all changed in 2000 when Ruvkun's lab discovered another microRNA that was present throughout the tree of life—from roundworms to mollusks, chickens, and humans.

At the time, the human genome was still being mapped, but the portion that was complete was available to researchers.

"I think it was probably one-third done, and I could already see (the new microRNA) in that one-third of the human genome," said Ruvkun. "That was a surprise!"

Since then, the microRNA field has exploded, with more than 170,000 citations currently listed in biomedical literature.

More than 1,000 microRNAs have been identified in human DNA, and some are already being used to better understand tumor types and develop treatments for people with chronic lymphocytic leukemia.

Trials are also underway to develop microRNAs as treatments for heart disease.

On the morning of their Nobel win, the two old friends "Facetimed and high-fived," Ruvkun said. "It's magnificent, and we're going to be celebrating like crazy."

genetic circuits, gene regulation, synthetic biology, transcription factors, promoter regions, CRISPR technology, inducible systems, feedback loops, RNA interference, protein engineering, biosensors, optogenetics, epigenetics, metabolic pathways, genome editing, cell differentiation, personalized medicine, drug delivery, microbial engineering, therapeutic applications.

#GeneticSwitches, #SyntheticBiology, #GeneTherapy, #CRISPR, #Optogenetics, #Bioengineering, #GeneRegulation, #Biotechnology, #Epigenetics, #PersonalizedMedicine, #GenomeEditing, #RNAInterference, #MetabolicEngineering, #PromoterRegions, #ProteinEngineering, #TissueEngineering, #DrugDelivery, #MicrobialEngineering, #Therapeutics, #Biosensors

International Conference on Genetics and Genomics of Diseases 

Comments

Popular posts from this blog

Fruitful innovation

Fruitful innovation: Transforming watermelon genetics with advanced base editors The development of new adenine base editors (ABE) and adenine-to-thymine/ guanine base editors (AKBE) is transforming watermelon genetic engineering. These innovative tools enable precise A:T-to-G and A:T-to-T base substitutions, allowing for targeted genetic modifications. The research highlights the efficiency of these editors in generating specific mutations, such as a flowerless phenotype in ClFT (Y84H) mutant plants. This advancement not only enhances the understanding of gene function but also significantly improves molecular breeding, paving the way for more efficient watermelon crop improvement. Traditional breeding methods for watermelon often face challenges in achieving desired genetic traits efficiently and accurately. While CRISPR/Cas9 has provided a powerful tool for genome editing, its precision and scope are sometimes limited. These limitations highlight the need for more advanced gene-e...

Genetic factors with clinical trial stoppage

Genetic factors associated with reasons for clinical trial stoppage Many drug discovery projects are started but few progress fully through clinical trials to approval. Previous work has shown that human genetics support for the therapeutic hypothesis increases the chance of trial progression. Here, we applied natural language processing to classify the free-text reasons for 28,561 clinical trials that stopped before their endpoints were met. We then evaluated these classes in light of the underlying evidence for the therapeutic hypothesis and target properties. We found that trials are more likely to stop because of a lack of efficacy in the absence of strong genetic evidence from human populations or genetically modified animal models. Furthermore, certain trials are more likely to stop for safety reasons if the drug target gene is highly constrained in human populations and if the gene is broadly expressed across tissues. These results support the growing use of human genetics to ...

Genetics study on COVID-19

Large genetic study on severe COVID-19 Bonn researchers confirm three other genes for increased risk in addition to the known TLR7 gene Whether or not a person becomes seriously ill with COVID-19 depends, among other things, on genetic factors. With this in mind, researchers from the University Hospital Bonn (UKB) and the University of Bonn, in cooperation with other research teams from Germany, the Netherlands, Spain and Italy, investigated a particularly large group of affected individuals. They confirmed the central and already known role of the TLR7 gene in severe courses of the disease in men, but were also able to find evidence for a contribution of the gene in women. In addition, they were able to show that genetic changes in three other genes of the innate immune system contribute to severe COVID-19. The results have now been published in the journal " Human Genetics and Genomics Advances ". Even though the number of severe cases following infection with the SARS-CoV-...